Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vanda Pharmaceutical (VNDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 708,345
  • Shares Outstanding, K 44,550
  • Annual Sales, $ 146,020 K
  • Annual Income, $ -18,010 K
  • 36-Month Beta 1.50
  • Price/Sales 4.91
  • Price/Cash Flow 0.00
  • Price/Book 5.60

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.40 +18.66%
on 05/31/17
16.50 -3.64%
on 06/22/17
+1.75 (+12.37%)
since 05/23/17
3-Month
13.20 +20.45%
on 05/03/17
16.50 -3.64%
on 06/22/17
+1.80 (+12.77%)
since 03/23/17
52-Week
10.42 +52.59%
on 06/24/16
18.00 -11.67%
on 09/22/16
+4.55 (+40.09%)
since 06/23/16

Most Recent Stories

More News
Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8%

Vanda Pharmaceuticals Inc. (VNDA) shares rose over 8% in the last trading session.

REGN : 517.33 (-1.75%)
VNDA : 15.90 (-1.24%)
Vanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in June 2017.

VNDA : 15.90 (-1.24%)
Research Reports Initiation on Biotech Stocks -- Corcept Therapeutics, Curis, OvaScience, and Vanda Pharma

On Friday, May 26, 2017, US markets saw a mixed session as 4 sectors closed in green, 2 sectors finished in red, and 3 sectors ended flat for the day. Major US indices were also mixed at the close of last...

CORT : 12.53 (+3.64%)
CRIS : 2.10 (-0.47%)
OVAS : 1.74 (-8.42%)
VNDA : 15.90 (-1.24%)
Watch for Vanda Pharmaceuticals to Potentially Pullback After Gaining 1.78% Yesterday

Vanda Pharmaceuticals (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $14.05 to a high of $14.50. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day...

VNDA : 15.90 (-1.24%)
Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31, 2017.

VNDA : 15.90 (-1.24%)
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 2, 2017 / Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) will be discussing their earnings results in their Q1 Earnings Call to be held May 2, 2017 at 4:30 PM Eastern Time.

VNDA : 15.90 (-1.24%)
Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will deliver a corporate presentation at the Deutsche Bank 42nd Annual Health Care Conference in Boston, Massachusetts on Thursday,...

VNDA : 15.90 (-1.24%)
DB : 16.64 (-0.60%)
Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017

Conference Call and Webcast to Follow

VNDA : 15.90 (-1.24%)
Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that it has entered into a license agreement with UC San Francisco (UCSF), under which Vanda will acquire an exclusive worldwide license...

VNDA : 15.90 (-1.24%)
How These Biotech Stocks are Faring? -- Corbus Pharma, Advaxis, Vanda Pharma, and Nivalis Therapeutics

On Monday, March 06, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Monday's trading session in bearish territories....

ADXS : 6.54 (+3.15%)
CRBP : 6.35 (+6.72%)
NVLS : 2.34 (+1.30%)
VNDA : 15.90 (-1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Support & Resistance

2nd Resistance Point 16.30
1st Resistance Point 16.10
Last Price 15.90
1st Support Level 15.75
2nd Support Level 15.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.